Menaflex — CPB 0786 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0786 covering the Menaflex device (HCPCS G0428), effective December 3, 2025. The position is unchanged — this device is experimental and not covered — but if your billing team hasn't built denial workflows around G0428, this update is your reminder to do it now.

Aetna's Menaflex coverage policy under CPB 0786 Aetna system classifies the Menaflex device as experimental, investigational, or unproven for all indications, including medial meniscus repair and reinforcement. HCPCS code G0428 — the collagen meniscus implant procedure code — is explicitly not covered for any of the diagnoses listed in this bulletin. If your orthopedic or sports medicine practice is billing G0428 to Aetna, every one of those claims will deny.

Quick-Reference Table

Aetna Menaflex Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Menaflex coverage policy under CPB 0786 is unambiguous. There are no coverage criteria to meet. Aetna does not recognize medical necessity for the Menaflex device — also known as the Collagen Meniscal Implant or Collagen Scaffold device — under any clinical circumstance.

This isn't a case where prior authorization might help. You can't satisfy a prior auth requirement when the payer's position is that the procedure is experimental. If your team submits G0428 expecting reimbursement from Aetna, the claim will deny, and an appeal won't succeed without a significant shift in Aetna's evidentiary standard.

The device is used for filling meniscal defects in the knee — specifically repair and reinforcement of the medial meniscus. Aetna's objection is clinical: insufficient evidence of effectiveness. That's a harder wall to argue around than a coverage exclusion based on billing technicalities.

The 33 ICD-10-CM diagnosis codes listed in this bulletin include osteoarthritis of the knee (M17.0–M17.9), internal derangement of the knee (M22.2x1–M23.92), meniscal tears (S83.211–S83.249), and osteochondritis dissecans (M93.261–M93.269). Aetna's policy covers all of them — but not in the direction you want. These are the diagnoses your practice would typically use to justify the procedure. Aetna is explicitly saying none of them qualify G0428 for coverage.

This is the kind of policy where your billing guidelines need to do the heavy lifting before a claim ever gets submitted.

Aetna Menaflex Exclusions and Non-Covered Indications

Every indication is excluded. That's the short version.

Aetna considers the Menaflex device experimental, investigational, or unproven for:

The phrase "all other indications" means there's no off-label path to coverage either. Some experimental designations leave a gap where a creative prior auth argument might work for a closely related indication. This policy closes that gap explicitly.

The device has gone through naming changes — Collagen Meniscal Implant, Collagen Scaffold device, and now Menaflex. Aetna's policy tracks all three names. If your practice or vendors use older terminology in documentation, the same non-covered status applies.

The real issue here is that some practices bill G0428 assuming the claim will deny but then pursue appeals as a matter of course. With an experimental designation and no coverage criteria to satisfy, that appeal strategy wastes time and resources. A denial from Aetna on G0428 is not a coding error or a documentation gap — it's a coverage policy decision.

Coverage Indications at a Glance

Aetna Menaflex Billing Guidelines and Action Items 2025

This policy has been in place — now modified as of December 3, 2025. Use that date as your audit trigger.

CPT, HCPCS, and ICD-10 Codes for Menaflex Under CPB 0786

Not Covered / Experimental HCPCS Codes

Key ICD-10-CM Diagnosis Codes

These are the diagnosis codes listed in CPB 0786. They represent the clinical scenarios where Menaflex might be considered — and where Aetna's non-coverage position applies.